Navigation Links
Nastech Announces Promotion of Gordon Brandt, M.D. to President
Date:12/20/2007

BOTHELL, Wash., Dec. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has promoted Gordon Brandt, M.D. to President of Nastech. Dr. Brandt previously held the title of Executive Vice President, Clinical Research and Medical Affairs. Dr. Steven Quay will remain the Company's Chairman and Chief Executive Officer.

"We are pleased to promote Gordon to the position of President of Nastech as he has been instrumental in progressing our technologies and programs over the past five years and in his new role he will have increased responsibilities in our business relationships and operations. Gordon has been the architect in designing and conducting multiple development programs which will yield Phase 2 results in 2008," stated Steven C. Quay, M.D., Ph.D., Chairman and CEO of Nastech. "This move will position Gordon for more active leadership in Nastech and allows me to increase my efforts on establishing MDRNA as an independent company concentrating on the development of RNA-based therapeutics, which we believe will eventually provide greater focus for both companies and enhance shareholder value."

"Nastech has developed a strong clinical pipeline of innovative therapeutics using our proprietary drug delivery technologies which are aimed at providing patients with a safe and effective method of administering their medications without an injection," stated Gordon Brandt, M.D., President of Nastech. "I look forward to advancing our business imperatives and clinical programs in the therapeutic areas we have targeted including osteoporosis, diabetes, and obesity."

Dr. Brandt joined Nastech in November, 2002 serving as the Executive Vice President, Clinical Research and Medica
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nastech to Host 2007 Analyst and Institutional Investor Day
2. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
3. Nastech Announces Third Quarter 2007 Financial Results
4. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
5. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
6. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
7. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... diagnostics company that develops and commercializes proprietary technologies ... announced that it has received approval from the ... 5,126,044 outstanding common share purchase warrants ("the Warrants") ... with the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/16/2015)... South Carolina (PRWEB) April 17, 2015 ... and steam system services, released their newly designed, ... The customer facing website effectively promotes the ... , All the information that a site ... steam system services, company capabilities, industries serviced, the ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... 8 LifeNet Health, a leading allograft bio-implant company, ... Tendon, both offering new options for ligament reconstruction. ... new bio-medical implants offer sports medicine physicians another alternative ... Tendon can be used in the reconstruction of either ...
... Dec. 8 Building on its flagship,suite of ... the Pyxis(R) MedStation(R) 4000 and an industry-first Performance,Analytics ... help improve medication safety. , ... medication dispensing system,offers new features that can help ...
... in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is ... , BETHESDA, Md., Dec. 8 ... company developing novel, proprietary antibodies for the treatment of ... data from a phase 2 clinical trial of BiTE(R) ...
Cached Biology Technology:LifeNet Health Introduces New Sports Medicine Bio-Implants 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 2Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 4Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 5
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... work and scientific adventure, marine explorers from more than ... Laboratory (MBL), today delivered the first global Census of ... and hides in the world,s oceans. In one of ... scientists spent over 9,000 days at sea on more ...
... survived for more than 400 million years, the horseshoe ... overharvest and habitat destruction. However, climatic changes may,also play ... how sensitive horseshoe crab populations are to natural climate ... Molecular Ecology . The horseshoe crab is ...
... Jerusalem, October 4, 2010 Researchers at the Hebrew University ... body that play a key role in controlling bone density, ... drug for prevention and treatment of osteoporosis and other bone ... researchers have just been published in the American journal ...
Cached Biology News:MBL scientists reveal findings of World Ocean Microbe Census 2MBL scientists reveal findings of World Ocean Microbe Census 3Climate change affects horseshoe crab numbers 2Hebrew University research holds promise for development of new osteoporosis drug 2
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
... a 10.0 kb Autographa californica (AcNPV) polyhedrin ... AcNPV polyhedrin promoter and two AcNPV p10 ... a Sma I cloning site, followed by ... inverted polyhedrin promoter has been inserted containing ...
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Biology Products: